Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Efficacy and safety of ustekinumab for the treatment of ulcerative colitis (UC) has been demonstrated in clinical trials, but few real-world data are available so far. The aim of this study was to assess effectiveness and safety of ustekinumab in a cohort of refractory UC patients.
Methods: Data of patients with moderate to severe UC treated with ustekinumab were retrospectively collected. Primary endpoint was steroid-free clinical remission at weeks 24 and 52 of therapy. Secondary endpoints were treatment response, endoscopic remission, treatment persistence at 12 months and safety.
Results: A total of 68 patients [males 63%; median (range) age 42 (16-72) years] were included. Almost all patients (97%) were biologics experienced. At weeks 24 and 52, 31% and 50% of patients achieved steroid-free clinical remission, 84% and 82% had clinical response, respectively. At the end of follow-up, there was a significant reduction of pMS from baseline (p < 0.001) and of steroid use (p < 0.001). At week 52, 22% of the available endoscopies (18/38) showed mucosal healing. The probability to persist in therapy at week 52 was 87%. Only one adverse event occurred.
Conclusions: Data from our real-life cohort of refractory UC patients suggest satisfactory effectiveness and a good safety of ustekinumab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14712598.2021.1981855 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of biosimilars in gastroenterology: a focus on inflammatory bowel disease management.
Expert Opin Biol Ther
September 2025
Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
Introduction: The introduction of biosimilars changed the management of biologicals in inflammatory bowel disease (IBD) since the approval of CT-P13, the first biosimilar to infliximab, by the European Medicines Agency (EMA) in September 2013 and by the U.S. Food and Drug Administration (FDA) in April 2016.
View Article and Find Full Text PDFCombination therapy with biologics and/or small molecules in inflammatory bowel disease: a comprehensive review.
J Crohns Colitis
September 2025
Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Advanced combination treatment (ACT)-the combination of two advanced agents such as biologics or small molecules-has emerged as a promising strategy in the management of inflammatory bowel disease refractory to conventional treatment, with severe extraintestinal manifestations, or with coexisting immune-mediated inflammatory diseases. ACT including complementary mechanisms of action aims to overcome the therapeutic ceiling observed with monotherapy. Its rationale is supported by preclinical and mechanistic data demonstrating synergistic immunological effects when distinct inflammatory pathways are targeted simultaneously.
View Article and Find Full Text PDFEfficacy and Safety of Ustekinumab in Treatment of Ulcerative Colitis: A Systematic Review.
Cureus
July 2025
Internal Medicine, Dr V.R.K Women's Medical College, Hyderabad, IND.
Ulcerative colitis (UC) is a chronic, relapsing, and remitting immune-mediated condition requiring long-term therapy. Moderate to severe disease is managed using steroids, sulfasalazine, thiopurines, biologicals [anti-tumor necrosis factor, anti-integrins, and anti-interleukin (IL) 12/23], and small molecules (janus kinase inhibitors, sphingosine-1-receptor modulators). Ustekinumab (UST) is an IgG1 monoclonal antibody acting on IL 12/23 recently authorized to treat moderate to severe UC that is not responsive to other biologic medicines.
View Article and Find Full Text PDFLong-term effectiveness and safety of ustekinumab in patients with Crohn's disease: real-world evidence.
Expert Opin Biol Ther
September 2025
Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China.
Background: Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist approved for the treatment of Crohn's disease (CD). Although UST has demonstrated good efficacy and safety in CD, long-term real-world data in Chinese patients are relatively scarce.
Methods: A single-center, observational retrospective study was conducted in the First Affiliated Hospital of Anhui Medical University.
Biosimilars for the Treatment of Moderate to Severe Chronic Plaque Psoriasis.
Psoriasis (Auckl)
August 2025
Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
Psoriasis is an immune-mediated chronic inflammatory skin disease affecting over 60 million adults and children worldwide and can occur at any age, from childhood to adulthood. If the patient has a diffuse form of psoriasis, affecting more than ten percent of the body surface, or involving sensitive areas such as the face, scalp, nails, and/or palmoplantar region, he or she is a candidate for systemic therapy. Currently, several drugs are approved for the treatment of moderate to severe chronic plaque psoriasis in Europe and US.
View Article and Find Full Text PDF